New York State Common Retirement Fund Grows Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

New York State Common Retirement Fund increased its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 49.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 33,581 shares of the company's stock after acquiring an additional 11,090 shares during the quarter. New York State Common Retirement Fund owned about 0.07% of Axsome Therapeutics worth $3,917,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Principal Financial Group Inc. grew its position in Axsome Therapeutics by 42.8% in the 1st quarter. Principal Financial Group Inc. now owns 295,671 shares of the company's stock worth $34,484,000 after purchasing an additional 88,606 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in Axsome Therapeutics in the 1st quarter worth $2,229,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Axsome Therapeutics by 20.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,642 shares of the company's stock worth $4,877,000 after purchasing an additional 9,928 shares during the last quarter. Trek Financial LLC acquired a new stake in Axsome Therapeutics in the 1st quarter worth $3,446,000. Finally, Price T Rowe Associates Inc. MD grew its position in Axsome Therapeutics by 12.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 31,228 shares of the company's stock worth $2,643,000 after purchasing an additional 3,366 shares during the last quarter. Institutional investors own 81.49% of the company's stock.

Axsome Therapeutics Price Performance

Shares of AXSM traded down $4.14 during midday trading on Friday, hitting $100.83. 854,936 shares of the company traded hands, compared to its average volume of 606,771. The stock has a 50-day moving average of $106.35 and a 200-day moving average of $109.81. Axsome Therapeutics, Inc. has a one year low of $72.21 and a one year high of $139.13. The firm has a market cap of $4.96 billion, a P/E ratio of -17.47 and a beta of 0.46. The company has a debt-to-equity ratio of 3.48, a current ratio of 2.03 and a quick ratio of 1.96.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Royal Bank Of Canada decreased their target price on shares of Axsome Therapeutics from $193.00 to $186.00 and set an "outperform" rating on the stock in a research report on Thursday, June 12th. Needham & Company LLC decreased their target price on shares of Axsome Therapeutics from $153.00 to $150.00 and set a "buy" rating on the stock in a research report on Monday, June 9th. Mizuho lifted their target price on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a research report on Thursday, March 27th. HC Wainwright reiterated a "buy" rating and set a $180.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, June 10th. Finally, Morgan Stanley assumed coverage on shares of Axsome Therapeutics in a research report on Thursday, July 3rd. They set an "overweight" rating and a $190.00 target price on the stock. One analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $172.33.

Insiders Place Their Bets

In other Axsome Therapeutics news, Director Mark Coleman sold 3,750 shares of the company's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $105.47, for a total value of $395,512.50. Following the completion of the sale, the director owned 50,387 shares of the company's stock, valued at $5,314,316.89. This represents a 6.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Mark L. Jacobson sold 25,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $110.44, for a total value of $2,761,000.00. Following the sale, the chief operating officer directly owned 5,783 shares of the company's stock, valued at approximately $638,674.52. This trade represents a 81.21% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 93,437 shares of company stock valued at $9,834,215 over the last quarter. 22.30% of the stock is owned by corporate insiders.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.